CelLBxHealth plc (AIM: CLBX), a circulating tumour cell (CTC) intelligence company headquartered in Guildford, UK, published its Q3 2026 trading update on 21 October 2026, revising full-year 2026 revenue guidance to approximately £1.8 million while simultaneously issuing FY 2027 revenue guidance in the range of £3.0 million to £4.0 million. The company reported that new business secured in Q3 trebled year-on-year to £0.3 million, and that its nine-month cash operating loss fell 60% to £4.0 million. Investors will be watching whether the company's operational realignment, new pharmaceutical partnerships, and anticipated £0.8 million R&D tax credit are sufficient to extend its cash runway through the near term.

Key Points

  • CelLBxHealth plc (AIM: CLBX) — a CTC solutions company operating from Guildford, UK and Plymouth Meeting, US
  • FY 2026 revenue guidance revised to approximately £1.8 million, representing 29% growth on FY 2025 revenues of £1.4 million
  • FY 2027 revenue forecast of £3.0 million to £4.0 million; cash of £1.4 million at 30 September 2026 with £0.8 million R&D tax credit anticipated
  • Investors should watch the CEO appointment process, cash runway into Q1 2027, and conversion of pipeline into contracted revenue

New Business Trebles in Q3 as Parsortix® Enters Radioligand-Therapy Market

CelLBxHealth secured £0.3 million of new business during Q3 2026, approximately three times the £0.1 million recorded in Q3 2025. The company signed a Master Services Agreement with a Swiss biotech company, followed by a Statement of Work covering a radiopharmaceutical clinical study — marking the Parsortix® platform's entry into the radioligand-therapy market. A further Statement of Work was signed with a US-based pharmaceutical company to process approximately 100 patient samples for downstream molecular analysis. The company also confirmed it secured an additional £0.1 million of new business in early October, following the quarter's close.

CelLBxHealth Cuts Nine-Month Cash Operating Loss by 60% to £4.0 Million

Disciplined cost management was a central theme of the Q3 update. For the nine months ending 30 September 2026, the cash operating loss fell 60% to £4.0 million, compared with £9.7 million in the corresponding period of 2025. Revenue booked in the quarter totalled £0.2 million. The company's average monthly cash burn in Q3 stood at £0.4 million. Management stated that planned Q4 reinvestment in product optimisation and new product development will increase average monthly cash expenditure by £0.1 million per month. With £1.4 million of cash at 30 September and the anticipated R&D tax credit of £0.8 million, the company expects a cash runway through to Q1 2027.

Parsortix® Platform Cited in Two Peer-Reviewed Oncology Publications During the Period

During Q3 2026, two independent clinical studies using Parsortix®-enriched circulating tumour cells were published in peer-reviewed journals. One study related to antibody-drug conjugate targeted therapies, and a second addressed the detection of brain cancer. The company stated these publications add to the body of evidence supporting the Parsortix® platform's potential across multiple areas of precision oncology. The platform, which harvests CTCs from blood and integrates with existing laboratory instruments, underpins three commercial revenue streams: product sales, laboratory services from a GCLP-compliant UK facility, and lab developed tests pursued through strategic partnerships.

CEO Search Under Way as Board Targets Sustainable Growth Into 2027

The Board confirmed it is progressing the appointment of a new Chief Executive Officer, with the stated aim of identifying a leader capable of driving the next phase of strategic development, strengthening commercial execution, and supporting future funding opportunities. Executive Chairman Dr Jan Groen continues to lead the business during this transition period. Management acknowledged that the operational realignment affected the timing of revenue recognition in 2026, resulting in the revised guidance of approximately £1.8 million. Looking ahead, the company anticipates FY 2027 revenues of £3.0 million to £4.0 million, citing increased commercial momentum and the benefits of improvements implemented during 2026.